You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 騰盛博藥-B(2137.HK)連續2日大漲 首隻國產新冠病毒中和抗體實現商業化
格隆匯 07-08 14:38
格隆匯7月8日丨騰盛博藥-B(2137.HK)再度拉昇漲約14%,2日累計漲幅高達25%,現報11.24港元,總市值81億港元。
公司及其旗下控股公司騰盛華創醫藥技術(北京)有限公司7日宣佈,其長效新冠中和抗體安巴韋單抗和羅米司韋單抗聯合療法在中國商業化上市。首批抗體藥物實現商業放行,標誌着這一聯合療法正式開啟商業化的重要里程碑。
據悉,首個國產新冠中和抗體聯合療法價格在1萬元以內,有三家經銷商,分別為華潤、國藥、上藥,通過他們再分發到全國各地,並正在溝通國家儲備事宜。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account